Valion Bio Partners with AFRRI/NIAID to Advance Entolimod for GI-ARS Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Key Partnership Agreement: Valion Bio has partnered with the Armed Forces Radiobiology Research Institute (AFRRI) and the National Institute of Allergy and Infectious Diseases (NIAID) to finalize the survival efficacy protocol for evaluating Entolimod™ in treating Gastrointestinal Acute Radiation Syndrome (GI-ARS), marking a significant advancement in radiation/nuclear countermeasures.
- Massive Market Opportunity: Entolimod is positioned as the potential first treatment for GI-ARS, representing a multi-billion-dollar commercial opportunity, particularly driven by U.S. government emergency preparedness requirements that highlight a critical therapeutic gap.
- Scientific Rigor: The AFRRI/NIAID-selected partial body irradiation model (PBI-BM2.5) meets FDA Animal Rule criteria, allowing for drug approval based on animal efficacy studies when human trials are unethical, showcasing Entolimod's potential in this context.
- Expansive Market Outlook: The global ARS medical countermeasures market is projected to reach $5.47 billion by 2025 and expand to $7.80 billion by 2032, growing at a CAGR of 5.2%, with North America accounting for 46% of market revenue, underscoring Valion Bio's strategic significance in this sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VBIO
Wall Street analysts forecast VBIO stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 0.533
Low
Averages
High
Current: 0.533
Low
Averages
High
No data
About VBIO
Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Valion Bio Partners with AFRRI/NIAID to Advance Entolimod for GI-ARS Treatment
- Key Partnership Agreement: Valion Bio has partnered with the Armed Forces Radiobiology Research Institute (AFRRI) and the National Institute of Allergy and Infectious Diseases (NIAID) to finalize the survival efficacy protocol for evaluating Entolimod™ in treating Gastrointestinal Acute Radiation Syndrome (GI-ARS), marking a significant advancement in radiation/nuclear countermeasures.
- Massive Market Opportunity: Entolimod is positioned as the potential first treatment for GI-ARS, representing a multi-billion-dollar commercial opportunity, particularly driven by U.S. government emergency preparedness requirements that highlight a critical therapeutic gap.
- Scientific Rigor: The AFRRI/NIAID-selected partial body irradiation model (PBI-BM2.5) meets FDA Animal Rule criteria, allowing for drug approval based on animal efficacy studies when human trials are unethical, showcasing Entolimod's potential in this context.
- Expansive Market Outlook: The global ARS medical countermeasures market is projected to reach $5.47 billion by 2025 and expand to $7.80 billion by 2032, growing at a CAGR of 5.2%, with North America accounting for 46% of market revenue, underscoring Valion Bio's strategic significance in this sector.
See More
Valion Bio Gains Support from FY27 NDAA for Radiation Countermeasures
- NDAA Support: The FY27 National Defense Authorization Act report from the U.S. House Armed Services Committee directs the Department of Defense to prioritize radiation/nuclear countermeasures, highlighting the significance of Valion Bio's candidate Entolimod and potentially paving the way for government support.
- Clinical Advantages of Entolimod: As a recombinant variant, Entolimod has demonstrated survival benefits as both a radioprotectant and radiomitigant in non-human primate studies, enhancing the company's competitive edge in radiation response solutions.
- Strategic Implications: CEO Michael Handley emphasized that the Department of Defense's focus indicates a national need for countermeasures effective before and after radiation exposure, providing a favorable opportunity for the company's future R&D and market positioning.
- R&D Prospects: Valion Bio is also advancing its next-generation TLR5 agonist, Entolasta, aimed at broader therapeutic applications, further solidifying the company's position in the biopharmaceutical sector, particularly in oncology supportive care.
See More
Valion Bio Presents Entolimod for Acute Radiation Syndrome to U.S. Officials
- Cross-Agency Collaboration: On May 14, 2026, Valion Bio presented Entolimod to senior officials from the U.S. Department of Defense and BARDA, reflecting ongoing government interest in the drug as a countermeasure for radiological threats, underscoring its strategic importance in national radiological preparedness.
- Oral Formulation Potential: The discussions highlighted the development of an oral formulation of Entolimod, which would provide operational advantages for mass casualty scenarios, supporting broader field deployment and national stockpile integration, thereby enhancing emergency response capabilities.
- Funding Support: To date, the Entolimod program has received over $140 million in investment, including approximately $35.6 million in non-dilutive U.S. government funding, demonstrating government recognition and support that strengthens its market competitiveness.
- Dual Protection Mechanism: As a TLR5 agonist, Entolimod offers dual protection for both bone marrow and gastrointestinal tissues, distinguishing it from existing single-target therapies, thereby improving survival rates at higher radiation doses and presenting significant clinical application prospects.
See More
Valion Bio Presents Entolimod as a Countermeasure for Acute Radiation Syndrome
- Cross-Agency Collaboration: On May 14, 2026, Valion Bio presented Entolimod to senior officials from the Department of Defense and BARDA, reflecting ongoing U.S. government interest in the drug as a countermeasure for radiological threats, particularly the potential for an oral formulation to enhance deployment in mass casualty scenarios.
- Strategic Significance: CEO Michael K. Handley noted that this engagement signals policymakers' recognition of Entolimod's strategic importance as a dual-tissue radiation countermeasure, emphasizing the operational realities of oral formulations for field deployment and national stockpile readiness.
- Funding and Research Support: To date, the Entolimod program has received over $140 million in investment, including approximately $35.6 million in non-dilutive U.S. government funding, demonstrating strong governmental confidence and support for the drug's development.
- Clinical Research Progress: Entolimod has shown a well-characterized safety and efficacy profile in 42 non-human primate studies and has been administered to around 300 human subjects, paving the way for its advancement toward a Biologics License Application with the FDA.
See More
Tivic Health Reports Q1 Non-GAAP Loss of $2.23 per Share
- Financial Performance: Tivic Health Systems reported a Q1 2026 non-GAAP loss per share of $2.23, with a net loss of $6.2 million, indicating significant financial pressure amid market competition.
- Operating Expenses: The company's operating expenses reached $5.6 million in Q1, reflecting an increase compared to the previous year, which may impact future profitability and cash flow management.
- Market Opportunity: Tivic Health outlines a significant opportunity in the $20 billion oncology market, demonstrating confidence in future growth following its strategic transformation.
- Funding Support: Valion Bio Inc. aims to complete GMP validation for Entolimod by the end of 2026, backed by NIAID funding, showcasing the company's proactive positioning in the biopharmaceutical sector.
See More
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook
- Financial Overview: Valion Bio reported a net loss of $6.2 million for Q1 2026, significantly up from a $1.5 million loss a year earlier, reflecting high operating costs associated with business expansion, although the loss per share improved from $2.52 to $2.23.
- R&D Spending Increase: Research and development expenses for the quarter reached $1.9 million, a substantial rise from $0.3 million in Q1 2025, indicating the company's ongoing commitment to accelerating the clinical development of Entolimod.
- Strategic Plans and Risks: Management highlighted future strategic initiatives, including initiating physician-sponsored studies for neutropenia in the second half of 2026, while also addressing financing and listing risks that could impact operational capabilities and market performance.
- Cash Flow Status: As of March 31, 2026, Valion Bio had cash and cash equivalents of $7.2 million, down from $12.6 million at the end of 2025, with $5 million used in operating activities during Q1, indicating pressure on the company's financial management.
See More
Valion Bio Partners with AFRRI/NIAID to Advance Entolimod for GI-ARS Treatment
- Key Partnership Agreement: Valion Bio has partnered with the Armed Forces Radiobiology Research Institute (AFRRI) and the National Institute of Allergy and Infectious Diseases (NIAID) to finalize the survival efficacy protocol for evaluating Entolimod™ in treating Gastrointestinal Acute Radiation Syndrome (GI-ARS), marking a significant advancement in radiation/nuclear countermeasures.
- Massive Market Opportunity: Entolimod is positioned as the potential first treatment for GI-ARS, representing a multi-billion-dollar commercial opportunity, particularly driven by U.S. government emergency preparedness requirements that highlight a critical therapeutic gap.
- Scientific Rigor: The AFRRI/NIAID-selected partial body irradiation model (PBI-BM2.5) meets FDA Animal Rule criteria, allowing for drug approval based on animal efficacy studies when human trials are unethical, showcasing Entolimod's potential in this context.
- Expansive Market Outlook: The global ARS medical countermeasures market is projected to reach $5.47 billion by 2025 and expand to $7.80 billion by 2032, growing at a CAGR of 5.2%, with North America accounting for 46% of market revenue, underscoring Valion Bio's strategic significance in this sector.
See More
Valion Bio Gains Support from FY27 NDAA for Radiation Countermeasures
- NDAA Support: The FY27 National Defense Authorization Act report from the U.S. House Armed Services Committee directs the Department of Defense to prioritize radiation/nuclear countermeasures, highlighting the significance of Valion Bio's candidate Entolimod and potentially paving the way for government support.
- Clinical Advantages of Entolimod: As a recombinant variant, Entolimod has demonstrated survival benefits as both a radioprotectant and radiomitigant in non-human primate studies, enhancing the company's competitive edge in radiation response solutions.
- Strategic Implications: CEO Michael Handley emphasized that the Department of Defense's focus indicates a national need for countermeasures effective before and after radiation exposure, providing a favorable opportunity for the company's future R&D and market positioning.
- R&D Prospects: Valion Bio is also advancing its next-generation TLR5 agonist, Entolasta, aimed at broader therapeutic applications, further solidifying the company's position in the biopharmaceutical sector, particularly in oncology supportive care.
See More
Valion Bio Presents Entolimod for Acute Radiation Syndrome to U.S. Officials
- Cross-Agency Collaboration: On May 14, 2026, Valion Bio presented Entolimod to senior officials from the U.S. Department of Defense and BARDA, reflecting ongoing government interest in the drug as a countermeasure for radiological threats, underscoring its strategic importance in national radiological preparedness.
- Oral Formulation Potential: The discussions highlighted the development of an oral formulation of Entolimod, which would provide operational advantages for mass casualty scenarios, supporting broader field deployment and national stockpile integration, thereby enhancing emergency response capabilities.
- Funding Support: To date, the Entolimod program has received over $140 million in investment, including approximately $35.6 million in non-dilutive U.S. government funding, demonstrating government recognition and support that strengthens its market competitiveness.
- Dual Protection Mechanism: As a TLR5 agonist, Entolimod offers dual protection for both bone marrow and gastrointestinal tissues, distinguishing it from existing single-target therapies, thereby improving survival rates at higher radiation doses and presenting significant clinical application prospects.
See More
Valion Bio Presents Entolimod as a Countermeasure for Acute Radiation Syndrome
- Cross-Agency Collaboration: On May 14, 2026, Valion Bio presented Entolimod to senior officials from the Department of Defense and BARDA, reflecting ongoing U.S. government interest in the drug as a countermeasure for radiological threats, particularly the potential for an oral formulation to enhance deployment in mass casualty scenarios.
- Strategic Significance: CEO Michael K. Handley noted that this engagement signals policymakers' recognition of Entolimod's strategic importance as a dual-tissue radiation countermeasure, emphasizing the operational realities of oral formulations for field deployment and national stockpile readiness.
- Funding and Research Support: To date, the Entolimod program has received over $140 million in investment, including approximately $35.6 million in non-dilutive U.S. government funding, demonstrating strong governmental confidence and support for the drug's development.
- Clinical Research Progress: Entolimod has shown a well-characterized safety and efficacy profile in 42 non-human primate studies and has been administered to around 300 human subjects, paving the way for its advancement toward a Biologics License Application with the FDA.
See More
Tivic Health Reports Q1 Non-GAAP Loss of $2.23 per Share
- Financial Performance: Tivic Health Systems reported a Q1 2026 non-GAAP loss per share of $2.23, with a net loss of $6.2 million, indicating significant financial pressure amid market competition.
- Operating Expenses: The company's operating expenses reached $5.6 million in Q1, reflecting an increase compared to the previous year, which may impact future profitability and cash flow management.
- Market Opportunity: Tivic Health outlines a significant opportunity in the $20 billion oncology market, demonstrating confidence in future growth following its strategic transformation.
- Funding Support: Valion Bio Inc. aims to complete GMP validation for Entolimod by the end of 2026, backed by NIAID funding, showcasing the company's proactive positioning in the biopharmaceutical sector.
See More
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook
- Financial Overview: Valion Bio reported a net loss of $6.2 million for Q1 2026, significantly up from a $1.5 million loss a year earlier, reflecting high operating costs associated with business expansion, although the loss per share improved from $2.52 to $2.23.
- R&D Spending Increase: Research and development expenses for the quarter reached $1.9 million, a substantial rise from $0.3 million in Q1 2025, indicating the company's ongoing commitment to accelerating the clinical development of Entolimod.
- Strategic Plans and Risks: Management highlighted future strategic initiatives, including initiating physician-sponsored studies for neutropenia in the second half of 2026, while also addressing financing and listing risks that could impact operational capabilities and market performance.
- Cash Flow Status: As of March 31, 2026, Valion Bio had cash and cash equivalents of $7.2 million, down from $12.6 million at the end of 2025, with $5 million used in operating activities during Q1, indicating pressure on the company's financial management.
See More
